Success Metrics

Clinical Success Rate

50.0%

Based on 6 completed trials

Completion Rate

50%(6/12)

Active Trials

0(0%)

Results Posted

150%(9 trials)

Terminated

6(50%)

Phase Distribution

Ph phase_3

75%

Ph phase_2

Ph not_applicable

Ph phase_4

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 2Efficacy & side effects

1(8.3%)

Phase 3Large-scale testing

9(75.0%)

Phase 4Post-market surveillance

1(8.3%)

N/ANon-phased studies

1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

6 of 12 finished

Non-Completion Rate

50.0%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(6)

Detailed Status

Terminated6

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (8.3%)

Phase 39 (75.0%)

Phase 41 (8.3%)

N/A1 (8.3%)

Trials by Status

terminated650%

completed650%

Recent Activity

0 active trials

Showing 5 of 12

terminatedphase_2

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555

completedphase_3

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

NCT00360243

View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials

NCT04002661Phase 2

Hypoactive Sexual Desire Disorder in Males

Terminated

NCT02770768Not Applicable

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

Terminated

NCT02714049Phase 4

Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy

Terminated

NCT00360555Phase 3

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Completed

NCT00360243Phase 3

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

Completed

NCT00360529Phase 3

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

Completed

NCT01057901Phase 3

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Terminated

NCT00441558Phase 3

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

Terminated

NCT00996372Phase 3

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Completed

NCT00996164Phase 3

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Completed

NCT01103362Phase 3

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Terminated

NCT00277914Phase 3

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

Completed

All 12 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 12